Suppr超能文献

一项聚焦于肝细胞癌中miR-141-3p下调及其临床病理意义的qRT-PCR和基因功能富集研究。

A qRT-PCR and Gene Functional Enrichment Study Focused on Downregulation of miR-141-3p in Hepatocellular Carcinoma and Its Clinicopathological Significance.

作者信息

Liu Cui-Zhen, Ye Zhi-Hua, Ma Jie, He Rong-Quan, Liang Hai-Wei, Peng Zhi-Gang, Chen Gang

机构信息

Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.

Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.

出版信息

Technol Cancer Res Treat. 2017 Dec;16(6):835-849. doi: 10.1177/1533034617705056. Epub 2017 Apr 23.

Abstract

BACKGROUND

The clinical significance of miR-141-3p in hepatocellular carcinoma has not been verified. Therefore, we conducted this study to examine miR-141-3p expression and its clinical significance in hepatocellular carcinoma and to investigate the functions of its potential targets.

METHODS

The Cancer Genome Atlas database and the Gene Expression Omnibus database were used to explore the aberrant expression of miR-141-3p in hepatocellular carcinoma. Furthermore, we assessed the miR-141-3p levels in 95 hepatocellular carcinoma tissues with 95 matched adjacent tissues using real-time quantitative polymerase chain reaction. Moreover, a target gene prediction analysis of miR-141-3p, a natural language processing analysis for hepatocellular carcinoma using PubMed, and a gene functional enrichment analysis were conducted to search the potential function of miR-141-3p in the pathogenesis of hepatocellular carcinoma.

RESULTS

Regarding The Cancer Genome Atlas data, miR-141-3p levels were markedly downregulated in hepatocellular carcinoma tissue compared to para- or nontumor tissue (4.6112 [1.7096] vs 5.3053 [1.4254], = .045). MiR-141-3p expression was reduced in patients with hepatocellular carcinoma with a low pathologic T stage ( = .006), a low grade ( = .01), elderly hepatocellular carcinoma patients ( = .001), and male patients with hepatocellular carcinoma ( = .01) compared with that in patients with hepatocellular carcinoma with high pathologic T stages, high grades, young patients with hepatocellular carcinoma, and female patients with hepatocellular carcinoma. However, according to the Gene Expression Omnibus database, no significant differences in the expression of miR-141-3p were observed between hepatocellular carcinoma tissue and normal liver tissue ( = .984). Real-time quantitative polymerase chain reaction confirmed a similar trend of decreased miR-141-3p in hepatocellular carcinoma tissue (1.7542 [0.8663] vs 2.5562 [1.7913], = .001) as observed in The Cancer Genome Atlas. In addition, decreased miR-141-3p levels were detected in the multiple tumor nodes group ( = .004), the metastasis group ( < .001), and the advanced TNM stage group ( = .01), compared to the single tumor nodes group, the nonmetastasis group, and the early TNM stage group. Two hundred eighty-two genes were identified from the overlap between the predicted targets and the natural language processing analysis. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed several significant biological functions and pathways related to the pathogenesis of cancers, including hepatocellular carcinoma.

CONCLUSION

Downregulation of miR-141-3p might be responsible for the carcinogenesis and aggressiveness of hepatocellular carcinoma. MiR-141-3p may act as an antitumor microRNA, which is essential for hepatocellular carcinoma progression through the regulation of various signaling pathways. Thus, interactions with miR-141-3p may provide a novel strategy for hepatocellular carcinoma treatment in the future.

摘要

背景

miR-141-3p在肝细胞癌中的临床意义尚未得到证实。因此,我们开展本研究以检测miR-141-3p在肝细胞癌中的表达及其临床意义,并探究其潜在靶标的功能。

方法

利用癌症基因组图谱数据库和基因表达综合数据库探究miR-141-3p在肝细胞癌中的异常表达。此外,我们采用实时定量聚合酶链反应评估了95例肝细胞癌组织及其95例配对癌旁组织中的miR-141-3p水平。此外,对miR-141-3p进行靶基因预测分析,利用PubMed对肝细胞癌进行自然语言处理分析,并进行基因功能富集分析,以探寻miR-141-3p在肝细胞癌发病机制中的潜在功能。

结果

关于癌症基因组图谱数据,与癌旁或非肿瘤组织相比,肝细胞癌组织中miR-141-3p水平显著下调(4.6112 [1.7096] 对5.3053 [1.4254],P = .045)。与高病理T分期、高分级、年轻肝细胞癌患者及女性肝细胞癌患者相比,低病理T分期(P = .006)、低分级(P = .01)、老年肝细胞癌患者(P = .001)及男性肝细胞癌患者的miR-141-3p表达降低。然而,根据基因表达综合数据库,肝细胞癌组织与正常肝组织之间miR-141-3p表达未观察到显著差异(P = .984)。实时定量聚合酶链反应证实,肝细胞癌组织中miR-141-3p呈类似的降低趋势(1.7542 [0.8663] 对2.5562 [1.7913],P = .001),与癌症基因组图谱观察结果一致。此外,与单肿瘤结节组、无转移组及早期TNM分期组相比,多肿瘤结节组(P = .004)、转移组(P < .001)及晚期TNM分期组(P = .01)中miR-141-3p水平降低。从预测靶标与自然语言处理分析的重叠部分鉴定出282个基因。基因本体论和京都基因与基因组百科全书通路分析揭示了与癌症发病机制相关的若干重要生物学功能和通路,包括肝细胞癌。

结论

miR-141-3p下调可能与肝细胞癌的发生发展及侵袭性有关。miR-141-3p可能作为一种抗肿瘤微小RNA,通过调控多种信号通路对肝细胞癌进展至关重要。因此,与miR-141-3p的相互作用可能为未来肝细胞癌治疗提供一种新策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f55/5762039/7fb21dc3b4de/10.1177_1533034617705056-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验